$21.22
0.00% yesterday
Nasdaq, May 20, 10:09 pm CET
ISIN
US3596641098
Symbol
FLGT

Fulgent Genetics Stock price

$21.22
+3.30 18.42% 1M
+3.94 22.80% 6M
+2.75 14.89% YTD
-0.52 2.39% 1Y
-34.86 62.16% 3Y
+5.53 35.25% 5Y
+12.04 131.15% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.00%
ISIN
US3596641098
Symbol
FLGT
Sector

Key metrics

Market capitalization $646.01m
Enterprise Value $329.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.13
P/S ratio (TTM) P/S ratio 2.21
P/B ratio (TTM) P/B ratio 0.58
Revenue growth (TTM) Revenue growth 1.71%
Revenue (TTM) Revenue $292.45m
EBIT (operating result TTM) EBIT $-71.92m
Free Cash Flow (TTM) Free Cash Flow $-31.61m
Cash position $320.32m
EPS (TTM) EPS $-1.34
P/E forward negative
P/S forward 2.08
EV/Sales forward 1.06
Short interest 10.48%
Show more

Is Fulgent Genetics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Fulgent Genetics Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Fulgent Genetics forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Fulgent Genetics forecast:

Buy
33%
Hold
67%

Financial data from Fulgent Genetics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
292 292
2% 2%
100%
- Direct Costs 187 187
0% 0%
64%
105 105
6% 6%
36%
- Selling and Administrative Expenses 103 103
3% 3%
35%
- Research and Development Expense 50 50
16% 16%
17%
-48 -48
9% 9%
-16%
- Depreciation and Amortization 24 24
15% 15%
8%
EBIT (Operating Income) EBIT -72 -72
0% 0%
-25%
Net Profit -41 -41
75% 75%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Fulgent Genetics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fulgent Genetics Stock News

Neutral
PRNewsWire
one day ago
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION  NEW YORK , May 19, 2025 /PRNewswire/ --  Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces   its investigation of potential breaches of fiduciary duty by the Board of Directors and senior management  of Fulgent Genetics, Inc. (NASDAQ: FLGT). Key Details: Subje...
Neutral
GlobeNewsWire
5 days ago
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Neutral
Seeking Alpha
18 days ago
Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript
More Fulgent Genetics News

Company Profile

Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Head office United States
CEO Ming Hsieh
Employees 1,313
Founded 2016
Website www.fulgentgenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today